Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

T cell therapy called AIC100, which targets the ICAM-1 protein, demonstrated encouraging responses and an acceptable safety profile in patients with two types of advanced thyroid cancer, according to ...

ICAM-1, a tumor-produced factor ... share additional insights from this research at the American Association of Cancer Research (AACR) Annual Meeting on April 29. The presentation, part of ...

Its lead candidate, AIC100, is an ICAM-1-directed CAR T therapy being developed for patients with advanced thyroid cancer. AffyImmune is developing a focused pipeline of therapeutics targeting ...

“This type of cancer is one of the deadliest and most ... AIC100 is a third generation CAR T cell therapy that works by binding to ICAM-1 on tumor cells to eliminate them. The CAR product ...